NeuroPace, Inc. (NASDAQ: NPCE) is a Healthcare company (Medical - Devices) with a market capitalization of $283M. The Maz Rating grades it against the other companies in its sector.
NeuroPace, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.20, NeuroPace, Inc. trades at 2.9x sales and 24.1x book value. Over the last twelve months it generated about $96M of revenue and a net loss of $20M. It runs a gross margin of 81.4%, an operating margin of -15.4% and a net margin of -20.0%. It shows return on equity of -133.1%, return on invested capital of -18.0% and a free cash flow yield of -4.4%. On the balance sheet: a debt-to-equity ratio of 6.05 and a current ratio of 5.26. Over the past 52 weeks the share price ranged from $5.46 to $19.60, with a beta of 1.93.
NeuroPace, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 9 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, NeuroPace, Inc. (NPCE) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 13.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.8% / 30% · Interest income / Revenue 2.21% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 13.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10.8% / 33% · Receivables / Mkt Cap (36m) 3.14% / 49% · Interest income / Revenue 2.21% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 13.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10.8% / 33.33% · Receivables / Mkt Cap (24m) 3.14% / 33.33% · Interest income / Revenue 2.21% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 61.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 54.5% / 33.33% · Receivables / Avg Assets (4Q) 14.8% / 33.33% · Interest income / Revenue 2.21% / 5% | Fail |
| FTSE | Debt / Total Assets 64.9% / 33.33% · (Cash+ST Inv) / Total Assets 51.9% / 33.33% · (Cash+Recv) / Total Assets 67.0% / 33.33% · Interest income / Revenue 2.21% / 5% | Fail |
It depends on the standard you follow. As of September 2026, NeuroPace, Inc. (NPCE) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. NeuroPace, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.21% of each dividend: NeuroPace, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.